These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21775829)

  • 1. Phase I trials: from traditional to newer approaches part II.
    Macaluso M; Krams M; Preskorn SH
    J Psychiatr Pract; 2011 Jul; 17(4):277-84. PubMed ID: 21775829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trials: from traditional to newer approaches. Part I.
    Macaluso M; Krams M; Preskorn SH
    J Psychiatr Pract; 2011 May; 17(3):200-3. PubMed ID: 21586998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive designs for Phase I dose-finding studies.
    Zhou Y
    Fundam Clin Pharmacol; 2010 Apr; 24(2):129-38. PubMed ID: 19703268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH; Plummer R
    Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A generic operational strategy to qualify translational safety biomarkers.
    Matheis K; Laurie D; Andriamandroso C; Arber N; Badimon L; Benain X; Bendjama K; Clavier I; Colman P; Firat H; Goepfert J; Hall S; Joos T; Kraus S; Kretschmer A; Merz M; Padro T; Planatscher H; Rossi A; Schneiderhan-Marra N; Schuppe-Koistinen I; Thomann P; Vidal JM; Molac B
    Drug Discov Today; 2011 Jul; 16(13-14):600-8. PubMed ID: 21570476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved up-and-down designs for phase I trials.
    Ivanova A; Montazer-Haghighi A; Mohanty SG; Durham SD
    Stat Med; 2003 Jan; 22(1):69-82. PubMed ID: 12486752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative approaches in drug development.
    Chang M; Kenley S; Bull J; Chiu YY; Wang W; Wakeford C; McCarthy K
    J Biopharm Stat; 2007; 17(5):775-89. PubMed ID: 17885865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designs for dose-escalation trials with quantitative responses.
    Bailey RA
    Stat Med; 2009 Dec; 28(30):3721-38. PubMed ID: 19579226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial designs for multiple myeloma.
    Hoering A; Crowley J
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004.
    Buoen C; Bjerrum OJ; Thomsen MS
    J Clin Pharmacol; 2005 Oct; 45(10):1123-36. PubMed ID: 16172177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal designs for estimating the most successful dose.
    Zohar S; O'Quigley J
    Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel strategies for microdose studies using non-radiolabeled compounds.
    Maeda K; Sugiyama Y
    Adv Drug Deliv Rev; 2011 Jun; 63(7):532-8. PubMed ID: 21345359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
    Wang M; Day R
    J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A SAS macro for target dose estimation by reinforced urn processes in phase I clinical trials.
    Zhong C; Zhuo Y; Xia J; Hu S; Li C; Jiang Z; Wang S
    Comput Methods Programs Biomed; 2011 Mar; 101(3):282-96. PubMed ID: 21329999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on 'Designs for dose-escalation trials with quantitative responses'.
    O'Quigley J
    Stat Med; 2009 Dec; 28(30):3745-50; discussion 3759-60. PubMed ID: 19967752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.